FILE PHOTO: An illustration, created at the Centers for Disease Control and Prevention (CDC), depicts the 2019 Novel CoronavirusMore
ZURICH (Reuters) - Switzerland's Relief Therapeutics and U.S. partner NeuroRx said on Wednesday they struck deals with Bachem and Nephron Pharmaceuticals to supply and make a 50-year-old drug, aviptadil, that is in clinical trials against COVID-19.
Relief and NeuroRx said the pact with Switzerland's Bachem, to supply peptides, and U.S. generics maker Nephron, to manufacture aviptadil, also being called RLF-100 by the companies, is aimed at having supplies sufficient to treat 1 million patients, should the drug prove effective in the studies.sonos sonos One (Gen 2) - Voice Controlled Smart Speaker with Amazon Alexa Built-in - Black read more
(This story has been refiled to correct date to September 30)
(Reporting by John Miller; Editing by Michael Shields)
all right reserved for yahoo news